Biography:
David Petch brings over 30 years of biotechnology expertise as founder and CEO/CSO of utR Biotech Ltd. With extensive experience in mammalian cell culture, fermentation processes, industrial scale-up, and cellular metabolism, he holds an M.Sc. and B.Sc. Honours in Microbiology from the University of Manitoba, plus certificates in IP/Technology Commercialization and Project Management. Since founding utR Biotech in 2016, David has pioneered integrating C-peptide into insulin formulations—a breakthrough approach addressing severe diabetic complications including cardiovascular disease, neuropathy, and Alzheimer's. His company recently partnered with Innoplexus to leverage AI in determining novel binding sites of C-peptide and insulin, opening new biological pathways for diabetes treatment. utR Biotech focuses on developing affordable diabetes therapeutics for underserved populations worldwide, combining scientific innovation with global health equity. David's published research includes peer-reviewed work on continuous cell culture metabolism in Biotechnology and Bioengineering.
Title : Beyond glucose: A dual mechanism neuroprotective strategy targeting the GPR146 SIRT1 and ADGRG1 MYC axes in alzheimer’s disease
Title : Restoring the axis: The interplay of C peptide Na K ATPase and the renin angiotensin system in the pathogenesis of diabetic complications
Title : AI receptor binding studies reveal GPR146 conformational states across diabetic phenotypes: Analysis of C peptide and insulin interactions in cholesterol metabolism cortisol regulation and the vitamin D renin angiotensin axis